• Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. 

  Dankner, M; Wang, Y; Fazelzad, R; Johnson, B; Nebhan, CA; Dagogo-Jack, I; Myall, NJ; Richtig, G; Bracht, JWP; Gerlinger, M (American Society of Clinical Oncology (ASCO), 2022-08-17)

  PURPOSE: Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to molecular ...

• Resistance Management for Cancer: Lessons from Farmers. 

  Seyedi, S; Harris, VK; Kapsetaki, SE; Narayanan, S; Saha, D; Compton, Z; Yousefi, R; May, A; Fakir, E; Boddy, AM (American Association for Cancer Research (AACR), 2024-11-15)

  One of the main reasons we have not been able to cure cancers is that treatments select for drug-resistant cells. Pest managers face similar challenges with pesticides selecting for pesticide-resistant insects, resulting ...

• Abstract B020: SF3B1  hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response 

  Bland, P; Saville, H; Wai, PT; Curnow, L; Nieminuszczy, J; Ravindran, N; Barker, HE; Wright, J; Yu, L; Mavrommati, I (American Association for Cancer Research (AACR), 2023-12-01)

• In silico targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer. 

  Azhar, Z; Grose, RP; Raza, A; Raza, Z (Open Exploration Publishing, 2023-08-31)

  AIM: Delineate structure-based inhibition of colony-stimulating factor-1 receptor (CSF1R) by small molecule CSF1R inhibitors in clinical development for target identification and potential lead optimization in cancer ...

• Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1 (Nov, 10.1038/s41388-02202513-5, 2022) 

  Coetzee, AS; Carter, EP; Rodriguez-Fernandez, L; Heward, J; Wang, Q; Karim, SA; Boughetane, L; Milton, C; Uyulur, F; Morton, JP (Springer Nature, 2023-01-20)

• Opposing roles for ADAMTS2 and ADAMTS14 in myofibroblast differentiation and function 

  Carter, E; Yoneten, K; Gavara, N; Tyler, E; Gauthier, V; Murray, E; Dijke, PT; Cameron, A; Pearce, O; Grose, R (Elsevier, 2023-06)

• Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1 

  Coetzee, AS; Carter, EP; Rodriguez-Fernandez, L; Heward, J; Wang, Q; Karim, SA; Boughetane, L; Milton, C; Uyulur, F; Morton, JP (Springer Nature, 2022-11-10)

• HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via <i>PHLDA1 </i>Induction 

  Clayton, NSS; Carter, EPP; Fearon, AEE; Heward, JAA; Fernandez, LR; Boughetane, L; Wilkes, EHH; Cutillas, PRR; Grose, RP (MDPI, 2023-03-25)

• Everybody needs good neighbours: the progressive DCIS microenvironment 

  V. Gibson, S; Roozitalab, RM; Allen, MD; Jones, JL; Carter, EP; Grose, RP (Elsevier, 2023-02-02)

• Targeting FGFR signalling as a therapeutic approach in pancreatic ductal adenocarcinoma 

  Wang, Q; Grose, R (Elsevier, 2023-06)

• Targeting pancreatic cancer: preclinical work 

  Marshall, J; Grose, R (Elsevier, 2023-06)

• ADAMTS3 restricts cancer invasion in models of early breast cancer progression through enhanced fibronectin degradation 

  Gibson, SV; Madzharova, E; Tan, AC; Allen, MD; auf dem Keller, U; Jones, JL; Carter, EP; Grose, RP (2023)

• The Future of Precision Oncology 

  Rulten, SL; Grose, RP; Gatz, SA; Jones, JL; Cameron, AJM (MDPI, 2023-08-09)

• Opposing roles for ADAMTS2 and ADAMTS14 in myofibroblast differentiation and function. 

  Carter, EP; Yoneten, KK; Gavara, N; Tyler, EJ; Gauthier, V; Murray, ER; Ten Dijke, P; Cameron, AJ; Pearce, O; Grose, RP (Wiley, 2023-11-06)

  Crosstalk between cancer and stellate cells is pivotal in pancreatic cancer, resulting in differentiation of stellate cells into myofibroblasts that drives tumour progression. To assess cooperative mechanisms in a 3D ...

• Interrogating the Impact of Protease Activity on Tumor Progression Using 3D Spheroid Models. 

  Gibson, SV; Carter, EP; Grose, RP (Springer Nature, 2023-12-02)

  Cancers have a complex relationship with the surrounding environment that regulates everything from progression to response to treatment. Cell-cell and cell-matrix interactions are heavily influenced by protease biology. ...

• Hypoxia-driven metabolic reprogramming of adipocytes fuels cancer cell proliferation 

  Aird, R; Wills, J; Roby, KF; Benezech, C; Stimson, RH; Wabitsch, M; Pollard, JW; Finch, A; Michailidou, Z (Frontiers Media, 2022-10-18)

• Spatiofunctional Dynamics of NKX3.1 to Safeguard the Prostate from Cancer 

  Finch, AJ; Baena, E (American Association for Cancer Research (AACR), 2021-09-01)

• Reversal of mitochondrial malate dehydrogenase 2 enables anaplerosis via redox rescue in respiration-deficient cells 

  Altea-Manzano, P; Vandekeere, A; Edwards-Hicks, J; Roldan, M; Abraham, E; Lleshi, X; Guerrieri, AN; Berardi, D; Wills, J; Junior, JM (Elsevier, 2022-11-02)

• Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia 

  Mian, SA; Philippe, C; Maniati, E; Protopapa, P; Bergot, T; Piganeau, M; Nemkov, T; Di Bella, D; Morales, V; Finch, AJ (American Association for the Advancement of Science (AAAS), 2023-03-01)

  Patients with myelodysplastic syndrome and ring sideroblasts (MDS-RS) present with symptomatic anemia due to ineffective erythropoiesis that impedes their quality of life and increases morbidity. More than 80% of patients ...

• Targets in the Tumour Matrisome to Promote Cancer Therapy Response. 

  Jalil, SMA; Henry, JC; Cameron, AJM (MDPI, 2024-05-11)

  The extracellular matrix (ECM) is composed of complex fibrillar proteins, proteoglycans, and macromolecules, generated by stromal, immune, and cancer cells. The components and organisation of the matrix evolves as tumours ...

View more